BIOTE CORP -A (BTMD) Stock Fundamental Analysis
USA - NASDAQ:BTMD - US0906831039 - Common Stock
2.98 USD
-0.02 (-0.67%)
2.98 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to BTMD. BTMD was compared to 196 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on BTMD.
1. Profitability
1.1 Basic Checks
In the past year BTMD was profitable.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
BTMD has a better Return On Assets (29.87%) than 98.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 51.55%, BTMD belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROIC | 51.55% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 15.73%, BTMD belongs to the top of the industry, outperforming 89.80% of the companies in the same industry.
In the last couple of years the Profit Margin of BTMD has declined.
BTMD has a Operating Margin of 17.79%. This is amongst the best in the industry. BTMD outperforms 86.73% of its industry peers.
BTMD's Operating Margin has declined in the last couple of years.
The Gross Margin of BTMD (71.89%) is better than 80.10% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.41 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.41, BTMD is doing good in the industry, outperforming 68.37% of the companies in the same industry.
BTMD has a debt to FCF ratio of 4.35. This is a neutral value as BTMD would need 4.35 years to pay back of all of its debts.
The Debt to FCF ratio of BTMD (4.35) is better than 84.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 2.41 |
ROIC/WACC5.26
WACC9.8%
2.3 Liquidity
A Current Ratio of 0.98 indicates that BTMD may have some problems paying its short term obligations.
BTMD has a Current ratio of 0.98. This is amonst the worse of the industry: BTMD underperforms 81.63% of its industry peers.
BTMD has a Quick Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 0.74. This is amonst the worse of the industry: BTMD underperforms 83.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 366.67%, which is quite impressive.
Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -14.94% in the last year.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
3.2 Future
BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.78% yearly.
Based on estimates for the next years, BTMD will show a small growth in Revenue. The Revenue will grow by 6.82% on average per year.
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BTMD is valuated cheaply with a Price/Earnings ratio of 3.04.
Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 97.45% of the companies listed in the same industry.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.68, the valuation of BTMD can be described as reasonable.
BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 87.76% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (23.32), we can say BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.04 | ||
| Fwd PE | 8.68 |
4.2 Price Multiples
BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 93.37% of the companies in the same industry.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.26 | ||
| EV/EBITDA | 7.14 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 24.88% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.98
-0.02 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners64.32%
Inst Owner Change-1.47%
Ins Owners9.75%
Ins Owner Change0.43%
Market Cap147.33M
Analysts81.67
Price Target5.51 (84.9%)
Short Float %2.91%
Short Ratio5.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.36%
Min EPS beat(2)178.65%
Max EPS beat(2)458.07%
EPS beat(4)3
Avg EPS beat(4)223.56%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)86.5%
EPS beat(12)6
Avg EPS beat(12)-127.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-2.07%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-2.3%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.04 | ||
| Fwd PE | 8.68 | ||
| P/S | 0.74 | ||
| P/FCF | 4.26 | ||
| P/OCF | 3.55 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.14 |
EPS(TTM)0.98
EY32.89%
EPS(NY)0.34
Fwd EY11.52%
FCF(TTM)0.7
FCFY23.49%
OCF(TTM)0.84
OCFY28.15%
SpS4.03
BVpS-1.72
TBVpS-2.01
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROCE | 65.25% | ||
| ROIC | 51.55% | ||
| ROICexc | 80.7% | ||
| ROICexgc | 137.37% | ||
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% | ||
| FCFM | 17.39% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover1.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 2.98 | ||
| Cap/Depr | 184.76% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 3.69 | ||
| Cash Conversion | 106.02% | ||
| Profit Quality | 110.56% | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 2.41 |
F-Score6
WACC9.8%
ROIC/WACC5.26
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)366.67%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%220%
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)-14.94%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.62%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-11.91%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year32.82%
EBIT Next 3Y16.27%
EBIT Next 5Y14.88%
FCF growth 1Y14.31%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y28.77%
OCF growth 3Y10.29%
OCF growth 5Y12.28%